PERGOVERIS 150 IU/75 IU

Dosage

Children: Refer to specific drug information for paediatric dosing guidelines, as this will also vary.

Adults: Refer to specific drug information for dosing guidelines, as this will vary widely.

Mechanism of action

The mechanism of action for 'alfa' cannot be defined without specific identification of the drug. Each compound named 'alfa' will have distinct mechanisms, typically involving receptor interaction, enzyme inhibition, or modulation of physiological pathways.

Pharmacodynamics

Pharmacodynamics will vary widely depending on the specific agent referred to as 'alfa'. Generally, pharmacodynamics describes how a drug affects the body, including its therapeutic effects, side effects, and the relationship between drug concentration and effect.

Pharmacokinetics

The pharmacokinetics of 'alfa' would also depend on the particular drug profile, including absorption, distribution, metabolism, and excretion (ADME). Parameters such as bioavailability, half-life, and clearance rates would need to be defined based on the specific agent.

Pregnancy

Consult healthcare provider for risk assessment.

Breast-feeding

Consult healthcare provider for risk assessment.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Infertility due to hypogonadotropic hypogonadism
• Assisted reproductive technologies, such as in vitro fertilization (IVF)
• Ovarian stimulation in women undergoing fertility treatments
• Male infertility due to insufficient spermatogenesis

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines in paediatric populations.

Adults: Refer to specific clinical guidelines and the BNF for dosing recommendations based on individual patient factors and treatment protocols.

Mechanism of action

Follitropin acts by binding to and activating the follicle-stimulating hormone receptor (FSHR) on the surface of ovarian granulosa cells and testicular Sertoli cells. This activation leads to a cascade of intracellular signaling pathways that promote the growth and maturation of ovarian follicles in women and stimulate spermatogenesis in men, thus facilitating fertility.

Pharmacodynamics

Follitropin enhances the ovarian response to gonadotropin stimulation, leading to increased estradiol production and follicular growth. In males, it stimulates Sertoli cells to support spermatogenesis. The pharmacodynamic effects of follitropin are dose-dependent, with higher doses generally resulting in a greater biological response, although individual responses may vary based on receptor sensitivity and other factors.

Pharmacokinetics

Follitropin is administered via subcutaneous injection, with peak plasma concentrations occurring approximately 12 to 24 hours post-injection. The half-life of follitropin is approximately 2 to 4 hours, but its biological effects last longer due to the continuous stimulation of the FSH receptor. It is primarily eliminated through renal pathways, and its pharmacokinetic profile can be influenced by factors such as patient age, body weight, and renal function.

Contra-indications

• Hypersensitivity to follitropin or any of its excipients
• Primary ovarian failure
• Pituitary or hypothalamic tumors
• Ovarian cysts or enlarged ovaries not due to polycystic ovary syndrome
• Pregnancy

Adverse effects

• Ovarian hyperstimulation syndrome (OHSS)
• Headache
• Abdominal pain
• Nausea
• Injection site reactions
• Multiple pregnancies
• Breast tenderness

Interactions

• Other gonadotropins may have additive effects
• Hormonal contraceptives may reduce the efficacy of follitropin
• Corticosteroids may affect ovarian response

Precautions

• Use with caution in patients with a history of thromboembolic events
• Monitor for signs of OHSS
• Assess ovarian response carefully during treatment
• Consider patient’s psychological state when undergoing fertility treatment

Pregnancy

Follitropin is contraindicated in pregnancy due to potential risks to the fetus.

Breast-feeding

Limited data available; caution is advised when administering to breastfeeding women.

Storage

Store in a refrigerator (2-8 degrees Celsius), do not freeze. Protect from light.

Formulations

• Follitropin alfa (recombinant)
• Follitropin beta (recombinant)

Indications

• Hypogonadism in males
• Infertility in females
• Assisted reproductive technology protocols

Dosage

Children: Refer to specific prescribing information and guidelines for pediatric dosing.

Adults: Refer to specific prescribing information and guidelines for dosage based on individual patient needs and treatment protocols.

Mechanism of action

Lutropin exerts its effects by binding to the luteinizing hormone receptor (LHR) located on the surface of target cells in the ovaries and testes. This binding activates the adenylate cyclase signaling pathway, leading to increased intracellular cyclic AMP (cAMP) levels. The rise in cAMP promotes steroidogenesis and gametogenesis, facilitating ovulation in females and testosterone production in males.

Pharmacodynamics

Lutropin influences several physiological processes related to reproduction. In females, it triggers the final maturation of ovarian follicles, leading to ovulation and the formation of the corpus luteum. In males, it stimulates the production of androgens, particularly testosterone, essential for spermatogenesis and the development of male secondary sexual characteristics. The hormonal balance maintained by lutropin is critical for fertility.

Pharmacokinetics

Lutropin is administered via subcutaneous or intramuscular injection, as it is a peptide hormone and is not effective when taken orally due to degradation in the gastrointestinal tract. After administration, it is absorbed into the bloodstream, where it has a half-life of approximately 20-30 minutes. The hormone is metabolized in the liver and kidneys, and its biological activity is primarily determined by its interaction with the LH receptor.

Contra-indications

• Hypersensitivity to lutropin or any of its components
• Tumors of the pituitary gland or hypothalamus
• Ovarian failure not due to hypogonadotropic hypogonadism

Adverse effects

• Headache
• Injection site reactions
• Ovarian hyperstimulation syndrome (OHSS)
• Nausea
• Abdominal pain
• Multiple pregnancies

Interactions

• Concomitant use with other gonadotropins may enhance ovarian response
• Caution should be exercised when used with medications that can affect hormonal levels

Precautions

• Monitor for signs of ovarian hyperstimulation syndrome
• Assess for adequate pituitary function before treatment
• Consider the risk of multiple pregnancies

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed.

Breast-feeding

It is unknown if lutropin is excreted in human milk. Caution should be exercised.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light.

Formulations

• Lutropin alfa injectable solution